BRAF35: The DNA-Binding Component of The BRCA2 Complex
Identification of BRAF35 mutations may be useful for identifying individuals at risk for breast cancer. The BRCA2/BRAF35 complex may be useful for the design or identification (via screen) of new cancer therapeutics. Antibodies to BRAF35 developed at Wistar may be useful tools for research and for diagnostic applications.
U.S. Patent No. 7,691,976.
This technology is available for exclusive or non-exclusive license. Sponsored research support to develop the technology will also be considered.